{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:29:27Z","timestamp":1771457367219,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2000,7,1]],"date-time":"2000-07-01T00:00:00Z","timestamp":962409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2000,7]]},"DOI":"10.1007\/bf03343751","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T10:33:12Z","timestamp":1394533992000},"page":"428-434","source":"Crossref","is-referenced-by-count":21,"title":["A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients"],"prefix":"10.1007","volume":"23","author":[{"given":"D. A.","family":"de Luis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lahera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. I.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"key":"BF03343751_CR1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch M.E., Elton R.L., Blackwell R.E. Bromocriptine as primary therapy for prolactinemicsecreting macroadenomas: results of a prospective multicentric study. J. Clin. Endocrinol. Metab. 1985, 60: 698\u2013705.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000184630","volume":"44","author":"A Colao","year":"1995","unstructured":"Colao A., Merola B., Sarnacchiaro F. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinoma. Horm. Res. 1995, 44: 222\u2013228.","journal-title":"Horm. Res."},{"key":"BF03343751_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0950-3552(05)80303-7","volume":"4","author":"PG Crosignani","year":"1990","unstructured":"Crosignani P.G., Ferrari C. Dopaminergic treatments for hyperprolactinemia. Baillieres Clin. Obstet. Gynaecol. 1990, 4: 441\u2013445.","journal-title":"Baillieres Clin. Obstet. Gynaecol."},{"key":"BF03343751_CR4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000182739","volume":"39","author":"R Razzaq","year":"1993","unstructured":"Razzaq R., O Halloran D.J., Beardwell C.G., Shalet S.M. The effects of CV 205-502 in patients with hyperprolactinemia intolerant and\/or resistant to bromocriptine. Horm. Res. 1993, 39: 218\u2013222.","journal-title":"Horm. Res."},{"key":"BF03343751_CR5","first-page":"577","volume":"74","author":"T Brue","year":"1992","unstructured":"Brue T., Pellegrini I., Gunz G. Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab. 1992, 74: 577\u2013584.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/09513599109028443","volume":"5","author":"D Gianola","year":"1992","unstructured":"Gianola D., Pedroncelli A., Montini M., Tengattini F., Pagani M.O., Cortesi L., Cappi M.P., Gherardi F., Lancranjan I., Pagani G. A new oral slow release form of bromocriptine, PARLODEL SRO, in the chronic treatment of 26 hyperprolactinemic patients. Gynecol. Endocrinol. 1992, 5: 213\u2013217.","journal-title":"Gynecol. Endocrinol."},{"key":"BF03343751_CR7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2265.1986.tb03279.x","volume":"24","author":"G Benker","year":"1992","unstructured":"Benker G., Gieshoff B., Freundieb O., Windeck R., Schulte H.M., Lancrajan I., Reinwein D. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours. Clin. Endocrinol. (Oxf.) 1992, 24: 505\u2013509.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03343751_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","volume":"72","author":"SWS Lamberts","year":"1991","unstructured":"Lamberts S.W.S., Quick R.F. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 1991, 72: 635\u2013641.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/jcem-68-6-1201","volume":"68","author":"C Ferrari","year":"1989","unstructured":"Ferrari C., Paracchi A., Mattei A.M., De Vicentis S., D\u2019Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 1989, 68: 1201\u20131205.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","volume":"37","author":"J Webster","year":"1992","unstructured":"Webster J., Piscitelli G., Polli A., D\u2019Alberton A., Falsetti L., Ferrari C., Fioretti P., Giordano G., L\u2019Hermite M., Ciccarelli E., Crosignani P.G., De Cecco L., Fadini R., Faglia G., Flamigni F., Tamburrano G., Scanlon M.F. Dose-dependent suppresion of serum prolactin by cabergoline in hyperprolactinemia: a placebo controlled, double blind, multicentre study. Clin. Endocrinol. (Oxf.) 1992, 37: 534\u2013539.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03343751_CR11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1530\/acta.0.1250170","volume":"125","author":"C Rasmussen","year":"1991","unstructured":"Rasmussen C., Brownell J., Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist. CV 205\u2013502. Acta Endocrinol. (Copenh.) 1991, 125: 170\u2013176.","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BF03343751_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1210\/jcem-68-2-336","volume":"68","author":"ML Vance","year":"1989","unstructured":"Vance M.L., Cragun J.R., Reimnitz C., Chang R.J., Rashet E., Blackwell R.E., Miller M.M., Molitch M.E. CV205\u2013502 treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 1989, 68: 336\u2013341.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03344963","volume":"17","author":"M Giusti","year":"1994","unstructured":"Giusti M., Porcella E., Carraro A., Cuttica M., Valenti S., Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J. Endocrinol. Invest. 1994, 17: 51\u201357.","journal-title":"J. Endocrinol. Invest."},{"key":"BF03343751_CR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"ML Vance","year":"1984","unstructured":"Vance M.L., Evans W.S., Thorner M.O. Bromocriptine. Ann. Intern. Med. 1984, 100: 78\u201381.","journal-title":"Ann. Intern. Med."},{"key":"BF03343751_CR15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","volume":"82","author":"AM Colao","year":"1997","unstructured":"Colao A.M., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. 1997, 82: 876\u2013883.","journal-title":"J. Clin. Endocrinol."},{"key":"BF03343751_CR16","first-page":"577","volume":"74","author":"T Brue","year":"1992","unstructured":"Brue T., Pellegrini I., Gunz G., Morange I., Dewailly D., Brownell J., Enjalbert A., Jaquet O. Effects of the dopamine agonist CV 205-502 in human prolactinoma as resistant to bromocriptine. J. Clin. Endocrinol. Metab. 1992, 74: 577\u2013582.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR17","first-page":"2338","volume":"81","author":"BMK Biller","year":"1996","unstructured":"Biller B.M.K., Molitch M.E., Vance M.L. Treatment of prolactin secreting macroadenoma with once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 1996, 81: 2338\u20132343.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343751_CR18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","volume":"69","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-standing ergoline derivation in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 1989, 69: 725\u2013728.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl.1","key":"BF03343751_CR19","first-page":"104","volume":"14","author":"S Grottoli","year":"1991","unstructured":"Grottoli S., Ciccarelli E., Mila C. Efficacy and tolerability of chronic therapy with cabergoline in patients with hyperprolactinemia. J. Clin. Invest. 1991, 14 (Suppl. 1): 104\u2013107.","journal-title":"J. Clin. Invest."},{"key":"BF03343751_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","volume":"40","author":"PFM Heijden Van der","year":"1991","unstructured":"Van der Heijden P.F.M., De Wit W., Brownell J., Schoemaker J., Rolland R. CV 205\u2013502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinemia. Eur. J. Obstet. Gynaecol. Reprod. Biol. 1991, 40: 111\u2013118.","journal-title":"Eur. J. Obstet. Gynaecol. Reprod. Biol."},{"key":"BF03343751_CR21","first-page":"11","volume":"16","author":"R Durante","year":"1991","unstructured":"Durante R., Giusti M., Carraro A. LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinemic patients. Minerva Endocrinologica 1991, 16: 11\u201316.","journal-title":"Minerva Endocrinologica"},{"key":"BF03343751_CR22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/0024-3205(88)90301-3","volume":"43","author":"RC Gaillard","year":"1988","unstructured":"Gaillard R.C., Brownell J. Hormonal effects of CV 205\u2013502, a novel octahydrobenzo( g)quinoline with potent dopamine agonist properties. Life. Sci. 1988, 43: 1355\u20131362.","journal-title":"Life. Sci."},{"key":"BF03343751_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/jcem-66-1-193","volume":"66","author":"AM Mattei","year":"1988","unstructured":"Mattei A.M., Ferrari C., Baroldi P. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 1988, 66: 193\u2013198.","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03343751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03343751\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03343751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:37:29Z","timestamp":1565257049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03343751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["BF03343751"],"URL":"https:\/\/doi.org\/10.1007\/bf03343751","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]}}}